Rheumatoid Arthritis Completed Phase 2 Trials for Olokizumab (DB13127)

Also known as: RA / Rheumatic Arthritis / Arthritis, Rheumatoid / Arthritis,Rheumatoid / Rheumatoid Arthritis (RA) / Rheumatoid Arthritis(RA) / Arthritis, Rheumatoid (RA) / Systemic rheumatoid arthritis / Arthritis rheumatoid / Rheumatoid arthritis, unspecified / R arthritis / Rh arthritis / Atrophic arthritis

IndicationStatusPhase
DBCOND0027961 (Rheumatoid Arthritis)Completed2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT01296711Open-label Study to Assess the Safety and Efficacy of CDP6038 in Patients Who Completed RA0056Treatment
NCT01533714The Long-term Safety and Efficacy of Olokizumab (CDP6038) With Active Rheumatoid ArthritisTreatment
NCT01242488Efficacy and Safety of CDP6038 in Patients With Rheumatoid Arthritis With an Unsuccessful Response to Anti-Tumor Necrosis Factor (Anti-TNF) TherapyTreatment
NCT01463059Efficacy and Safety of Olokizumab With Rheumatoid Arthritis With Previously Failed to Anti-tumor Necrosis Factor (Anti-TNF) TherapyTreatment